Does beetroot juice improve walking in people with lung disease and low oxygen levels?

Submission date 03/07/2015	Recruitment status No longer recruiting	[X] Prospectively registered [_] Protocol
Registration date 14/07/2015	Overall study status Completed	 [_] Statistical analysis plan [X] Results
Last Edited 18/07/2023	Condition category Respiratory	Individual participant data

Plain English summary of protocol

Background and study aims

Despite optimum medical treatment, many patients with lung disease remain significantly disabled. There is evidence that dietary nitrate supplementation can reduce the oxygen needed during exercise but it is not clear if this improves the amount of exercise that a person can do. The purpose of this project is to investigate whether dietary nitrate supplementation in the form of a single dose of beetroot juice can improve the distance that people with lung disease who are dependent on oxygen can walk.

Who can participate?

Adults with lung disease who need to use oxygen when they walk.

What does the study involve?

Participants are randomly allocated into one of two groups. Those in group 1 are given 140 ml of nitrate-rich beetroot juice (0.8 g nitrate) to drink. Those in group 2 are given 140 ml of placebo (nitrate-depleted beetroot juice). All participants are then asked to do a walking test (called an "endurance shuttle walk"). How long each participant can walk for and the effects of the nitrate-rich beetroot juice on heart rate and amount of oxygen in the blood is recorded.

What are the possible benefits and risks of participating?

The tests used are all part of routine clinical practice and no significant risks are anticipated. As this is a test of a single dose only, no direct benefit to trial participants is expected but they will be helping to advance understanding of exercise limitation and this could eventually lead to a novel therapy becoming available for them and others with their condition.

Where is the study run from? Royal Brompton and Harefield NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for? October 2015 to July 2024

Who is funding the study? Moulton Medical Foundation (Guernsey) Who is the main contact? Mansour Majrshi, m.majrshi22@imperial.ac.uk

Contact information

Type(s) Public

Contact name Mr Mansour Majrshi

Contact details

Respiratory Muscle Lab National Heart and Lung Institute Royal Brompton Campus Guy Scadding Building Dovehouse St London United Kingdom SW3 6LY +44 (0)2073518029 m.majrshi22@imperial.ac.uk

Type(s)

Scientific

Contact name Dr Nicholas Hopkinson

ORCID ID http://orcid.org/0000-0003-3235-0454

Contact details

Royal Brompton Hospital Fulham Rd London United Kingdom SW3 6NP

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

The effect of dietary nitrate on exercise in hypoxia

Acronym

EDEN-OX

Study objectives

Current hypothesis as of 11/01/2023:

The purpose of this study is to investigate the effects of an acute administration of beetroot (BR) juice versus placebo beverage ingestion on plasma NO2 levels, blood pressure, exercise tolerance and fractional oxygen extraction in 4 groups of patients

1. COPD patients who are using ambulatory oxygen

2. Interstitial pulmonary Fibrosis (IPF) patients who are using ambulatory oxygen

3. Pulmonary hypertension (PHT) patients who are using ambulatory oxygen

4. Adults with a history of COVID-19 and persisting breathlessness at least 3 months following the acute illness and evidence of pulmonary vascular abnormalities

The following hypotheses will be tested:

- 1. BR would increase plasma NO2- levels (a biomarker of NO production and availability)
- 2. BR will increase endurance shuttle walk time
- 3. BR will reduce oxygen desaturation during ESWT (area under SaO2 curve to isotime)
- 4. BR will reduce heart rate during equivalent exercise (area under HR curve to isotime)

Previous hypothesis:

The purpose of this study is to investigate the effects of an acute administration of beetroot (BR) juice versus placebo beverage ingestion on plasma NO2- levels, blood pressure, exercise tolerance and fractional oxygen extraction in 3 groups of patients

1. COPD patients who are using ambulatory oxygen

2. Interstitial pulmonary Fibrosis (IPF) patients who are using ambulatory oxygen

3. Pulmonary hypertension (PHT) patients who are using ambulatory oxygen

The following hypotheses will be tested:

- 1. BR would increase plasma NO2- levels (a biomarker of NO production and availability)
- 2. BR will increase endurance shuttle walk time
- 3. BR will reduce oxygen desaturation during ESWT (area under SaO2 curve to isotime)
- 4. BR will reduce heart rate during equivalent exercise (area under HR curve to isotime)

Ethics approval required

Old ethics approval format

Ethics approval(s)

London-Chelsea Research Ethics Committee, ref: 15/LO/0975

Study design

Series of parallel randomised, double-blind, cross-over, placebo-controlled trial

Primary study design

Interventional

Secondary study design

Randomised cross over trial

Study setting(s) Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Patients with lung disease (COPD, interstitial pulmonary fibrosis, pulmonary hypertension) who require ambulatory oxygen because of exertional desaturation and adults with a history of COVID-19 and persisting breathlessness at least 3 months following the acute illness and evidence of pulmonary vascular abnormalities

Interventions

140 ml of nitrate-rich beetroot juice (containing 12.9 mmol nitrate) or nitrate-depleted placebo.

Intervention Type

Supplement

Primary outcome measure

An increase in endurance shuttle walk (ESWT) time breathing oxygen at the patient's customary flow rate.

Secondary outcome measures

- 1. Area under oxygen saturation curve to isotime during ESWT
- 2. Area under heart rate curve to isotime during ESWT
- 3. Resting blood pressure
- 4. Blood nitrate levels

Overall study start date

01/10/2015

Completion date

01/07/2024

Eligibility

Key inclusion criteria

Current inclusion criteria as of 18/07/2023:

1. Adult patients with GOLD I-IV COPD who require ambulatory oxygen because of exertional desaturation

2. Adult patients with IPF who require ambulatory oxygen because of exertional desaturation

3. Adult patients with pulmonary hypertension who require ambulatory oxygen because of

exertional desaturation

4. Adults with a history of COVID-19 and persisting breathlessness at least 3 months following the acute illness and evidence of pulmonary vascular abnormalities (abnormal gas transfer defined as a TLco <lower limit of normal)

Previous inclusion criteria as of 11/01/2023:

1. Adult patients with GOLD I-IV COPD who require ambulatory oxygen because of exertional desaturation

 Adult patients with IPF who require ambulatory oxygen because of exertional desaturation
 Adult patients with pulmonary hypertension who require ambulatory oxygen because of exertional desaturation

4. Adults with a history of COVID-19 and persisting breathlessness at least 3 months following the acute illness and evidence of pulmonary vascular abnormalities

Previous inclusion criteria:

1. Adult patients with GOLD I-IV COPD who require ambulatory oxygen because of exertional desaturation

 Adult patients with IPF who require ambulatory oxygen because of exertional desaturation
 Adult patients with pulmonary hypertension who require ambulatory oxygen because of exertional desaturation

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

90

Key exclusion criteria

- 1. Clinically unstable patients (within one month of exacerbation)
- 2. Significant comorbidity limiting exercise tolerance
- 3. Significant renal impairment (estimated glomerular filtration rate (eGFR) <50 ml.min-1)
- 4. Hypotension (systolic blood pressure <100 mmHg)
- 5. Pregnancy
- 6. Use of nitrate based medication or PDE5 inhibitors such as sildenafil

Date of first enrolment

01/10/2015

Date of final enrolment

01/06/2024

Locations

Countries of recruitment England

United Kingdom

Study participating centre Royal Brompton and Harefield NHS Foundation Trust Fulham Rd London United Kingdom SW3 6NP

Sponsor information

Organisation Imperial College

Sponsor details Regulatory Compliance Imperial College London and Imperial College Healthcare NHS Trust Room 510A 5th floor Lab Block Charing Cross Hospital Fulham Palace Road London England United Kingdom W6 8RF

Sponsor type University/education

ROR https://ror.org/041kmwe10

Funder(s)

Funder type Charity

Funder Name Moulton Medical Foundation

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

01/12/2024

Individual participant data (IPD) sharing plan

The deidentified datasets generated during the current study will be available indefinitely to researchers upon request to Professor Nicholas Hopkinson (n.hopkinson@ic.ac.uk) once the results have been published in a scientific journal.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	Results for COPD group	01/12/2021	03/12/2021	Yes	No
<u>HRA research summary</u>			28/06/2023	No	No